

Bhagwan Yadav

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4072734/publications.pdf>

Version: 2024-02-01

46
papers

2,413
citations

346980

22
h-index

371746

37
g-index

49
all docs

49
docs citations

49
times ranked

4748
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	7.7	73
2	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2022, 6, e701.	1.2	4
3	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. <i>Cancers</i> , 2021, 13, 2907.	1.7	3
4	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784.	3.3	6
5	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848.	2.2	11
6	Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. <i>Journal of Biological Chemistry</i> , 2020, 295, 4194-4211.	1.6	48
7	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604.	1.8	68
8	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720.	1.7	99
9	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. <i>Npj Systems Biology and Applications</i> , 2019, 5, 20.	1.4	32
10	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncolmmunology</i> , 2019, 8, e1638210.	2.1	19
11	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1360-1372.	3.3	40
12	Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer. <i>Methods in Molecular Biology</i> , 2019, 1888, 205-217.	0.4	7
13	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	5.8	107
14	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2060-2071.	1.9	33
15	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	116
16	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	0.9	74
17	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , 2017, 144, 621-630.	0.6	26
18	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. <i>Blood</i> , 2017, 130, 789-802.	0.6	90

#	ARTICLE	IF	CITATIONS
19	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854.	0.6	1
20	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350.	0.8	35
21	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527.	0.8	28
22	Consistency in drug response profiling. <i>Nature</i> , 2016, 540, E5-E6.	13.7	76
23	Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. <i>Molecular Cancer</i> , 2016, 15, 34.	7.9	57
24	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. <i>Blood</i> , 2016, 128, 2921-2921.	0.6	0
25	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. <i>Blood</i> , 2016, 128, 4711-4711.	0.6	0
26	From drug response profiling to target addiction scoring in cancer cell models. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1255-1264.	1.2	13
27	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309.	2.8	19
28	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. <i>Chemistry and Biology</i> , 2015, 22, 1144-1155.	6.2	22
29	Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. <i>Computational and Structural Biotechnology Journal</i> , 2015, 13, 504-513.	1.9	485
30	Abstract P6-02-01: Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors. , 2015, , .		0
31	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. <i>Blood</i> , 2015, 126, 867-867.	0.6	0
32	Suppression of BRCA1 sensitizes cells to proteasome inhibitors. <i>Cell Death and Disease</i> , 2014, 5, e1580-e1580.	2.7	21
33	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193.	1.6	243
34	Abstract 5384: Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs. , 2014, , .		0
35	Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. <i>Blood</i> , 2014, 124, 2160-2160.	0.6	0
36	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. <i>Blood</i> , 2014, 124, 3505-3505.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046.	0.6	3
38	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. <i>Blood</i> , 2014, 124, 2163-2163.	0.6	1
39	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	7.7	334
40	Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. <i>PLoS Computational Biology</i> , 2013, 9, e1003226.	1.5	84
41	Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. <i>Cell Death and Disease</i> , 2013, 4, e742-e742.	2.7	41
42	Abstract 5588: Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal additions.. , 2013, , .		0
43	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. <i>Blood</i> , 2013, 122, 1668-1668.	0.6	0
44	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	0.6	0
45	Obatoclox, Saliphenylhalamide, and Gemcitabine Inhibit Influenza A Virus Infection. <i>Journal of Biological Chemistry</i> , 2012, 287, 35324-35332.	1.6	80
46	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	0.6	1